The Revised Horizontal Block Exemption Regulations: Considerations for the Pharma Sector

Purchase access to view full content
The Revised Horizontal Block Exemption Regulations: Considerations for the Pharma Sector

The Revised Horizontal Block Exemption Regulations: Considerations for the Pharma Sector

About the speakers
  • Laetitia Szaller
    Laetitia Szaller
    Business Advisor at General Counsel
    Laetitia has over 18 years’ experience in multiple sectors, including 14 in the pharmaceuticals and medical device industry. She joined AM-Pharma in April 2020 as General Counsel and VP Business Development. Before joining AM-Pharma, Laetitia was at UCB as global Associate General Counsel BD, M&A and Antitrust. Prior to that, she was Legal Director, Emerging Markets EMEA, Central European Region and Benelux at Zoetis (Pfizer former animal health division) and has also led the EMEA legal department for the Abbott Vascular division at Abbott. She also held global positions at the Carlson Rezidor Hotel Group and at the automotive division (Wabco) at American Standard. Laetitia holds a Master’s degree in International and Comparative Law from the Vrije Universiteit Brussel and is a qualified lawyer in both the UK and Belgium, with extensive international experience, regularly speaking at various legal conferences.
  • Chris Verleye
    Chris Verleye
    Senior Legal Director at Johnson & Johnson
  • Sibel Yilmaz
    Sibel Yilmaz
    Partner at Covington & Burling
    Sibel Yilmaz advises on all aspects of competition law, foreign investment and foreign subsidies screening, with a focus on the life sciences, technology and private equity sectors. Sibel has particular expertise in the life sciences sector and has been involved in some of the industry's most high profile matters in recent years, including representing Novartis on its $30 billion acquisition of GSK’s oncology business, advising Takeda on its sale of certain respiratory products to AstraZeneca and representing clients in several investigations relating to alleged excessive prices and other non-competitive practices in the life science sector. Sibel is ranked among the world's top antitrust practitioners by Global Competition Review, who included her in their most recent 40 Under 40 survey, as well as Chambers Global. She is described as "a brilliant and promising lawyer, who is highly recommended for complex merger work” and “an exceptional talent”, "absolutely a tip for the top." Sibel received her LL.M. in Law and Economics from the University of Rotterdam and Master of Law from Stockholm University and is admitted to practice in Belgium and Sweden.
  • Cristiane Ferreira
    Cristiane Ferreira
    Senior Legal Director at Alnylam Pharmaceuticals
    Cristiane Ferreira, Sr. Legal Director, Partner & Emerging Markets at Alnylam Pharmaceuticals. Cristiane is an experienced legal executive, with over 15 years of experience, mainly in the pharmaceutical industry, supporting different regions and countries, including LATAM, Canada, Europe, Middle East and Asia. Cristiane joined Alnylam in 2019, progressing from Legal and Compliance Director for LATAM & Canada to Sr. Legal Director for Partner & Emerging Markets, which is a region that covers 50+ countries. Before joining Alnylam, Cristiane worked at Aegerion Pharmaceuticals, Smith & Nephew and Abbott Laboratories. During the course of her career, Cristiane has advised companies on a vast range of complex issues, including competition, compliance, privacy, regulatory, market access and commercial. Cristiane holds a LLM in International and European Law from Vrije Universiteit Brussel (VUB), Brussels, Belgium, and a MBA from Fundação Getulio Vargas, São Paulo Brazil.

Key takeaways